Literature DB >> 2884326

A case of MAO inhibitor/MDMA interaction: agony after ecstasy.

M J Smilkstein, S C Smolinske, B H Rumack.   

Abstract

After ingesting 3,4-methylene-dioxy-methamphetamine (MDMA) and the monoamine oxidase (MAO) inhibitor phenelzine, a 50 year old male developed marked hypertension, diaphoresis, altered mental status, and hypertonicity lasting 5-6 hours. This clinical course is typical of interaction between MAO inhibitors and some sympathomimetics including amphetamines. Such interaction has not previously been described involving MDMA. Sympathomimetic-MAO inhibitor interactions can cause excessive release of endogenous bioactive amines (e.g. norepinephrine, serotonin). Hypertensive crisis, intracranial hemorrhage, hypertonicity, and severe hyperthermia have occurred due to sympathomimetic-MAO inhibitor interactions. MDMA shares structural and pharmacologic features with other agents capable of causing this interaction, and this case suggests that MDMA can cause significant toxicity in patients taking MAO inhibitors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884326     DOI: 10.3109/15563658708992620

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  7 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

Authors:  U D McCann; S O Slate; G A Ricaurte
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 3.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

Review 4.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 5.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Authors:  A R Green; A J Cross; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

Review 6.  Clinical features and management of intoxication due to hallucinogenic drugs.

Authors:  J B Leikin; A J Krantz; M Zell-Kanter; R L Barkin; D O Hryhorczuk
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

7.  Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities.

Authors:  Luther Elliott; Christopher Keith Haddock; Stephanie Campos; Ellen Benoit
Journal:  PLoS One       Date:  2019-12-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.